Skip to content
Screener

Artiva Biotherapeutics, Inc. ARTV Q1 2026 Annual earnings

Reported May 8, 2026 · Before market open

EPS-$0.95Miss by $0.07
EPS estimate-$0.88

Next report

Date not yet announced

Financials

Q1 2026

Income statement

See full
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$159.18M+118%
Enterprise value$148.02M+163%

Returns & leverage

See full
Return on equity-67.9%—
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

FAQ

When did Artiva Biotherapeutics, Inc. report Q1 2026 earnings?
Artiva Biotherapeutics, Inc. (ARTV) reported Q1 2026 earnings on May 8, 2026 before market open.
What were Artiva Biotherapeutics, Inc.'s Q1 2026 revenue and EPS?
Artiva Biotherapeutics, Inc. reported eps of $-0.95 for Q1 2026.
Did Artiva Biotherapeutics, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.88 by $0.07.
How did Artiva Biotherapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 14.5% from $-0.83.
Where can I find Artiva Biotherapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-213239) and the 10-K/A periodic report (0001193125-26-197115) directly on SEC EDGAR. The filing index links above go to sec.gov.